Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs

Executive Summary

GDUFA funding will bring 50 additional people to the Office of Pharmaceutical Quality for generic drug review purposes.


Related Content

ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
EpiPen Generics: Woodcock Explains Injector Studies
Scrutiny Of EpiPen Pricing Invited By Mylan Lobbying, Congressman Says
ANDA Approvals, Submissions Decline With New Review Goal Coming
REMS Abuse Legislation: GPhA and PhRMA Set To Battle Again
ANDA Approval Speed-Up Leaves Sponsors With Less Margin For Error
FDA’s Generic Drug Staff To Be Reduced When Workload Under Control
Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters
REMS And Generics: GPhA Needs Legislation, Continues Education


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts